Previous 10 | Next 10 |
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medic...
– Phase 1 data provide rationale for sebetralstat as short-term prophylaxis for medical and dental procedures - – Patient survey data demonstrate treatment burden associated with injectable on-demand treatments for HAE - KalVista Pharmaceuticals, Inc. (NASDAQ: KA...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 13th C1-inhibitor Deficiency & Angioedem...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcar...
2023-03-29 17:30:23 ET Gainers: Erasca ( ERAS ) +8% . KalVista Pharmaceuticals ( KALV ) +5% . Ramaco Resources ( METC ) +5% . Pyxis Oncology ( PYXS ) +5% . Yellow Corporation ( YELL ) +5% . Losers: Semtech ( SMTC ...
2023-03-09 07:17:48 ET KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q3 GAAP EPS of -$0.75 beats by $0.26 . Cash, cash equivalents and marketable securities were $171.7 million as of January 31, 2023, compared to $166.2 million as of April 30, 2022. For...
– Orally disintegrating tablet formulation shows similar pharmacokinetics to current film-coated tablets supporting lifecycle extension in US and EU - – Real-word evidence and patient survey data demonstrate treatment burden associated with the administration of injectable...
Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting for the Ameri...
KalVista Pharmaceuticals ( NASDAQ: KALV ) reported clinical trial and regulatory updates for its lead drug sebetralstat, a potential oral on-demand therapy for hereditary angioedema (HAE) attacks. The company recently received additional FDA regulatory guidance for the oral disintegra...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...